The soluble fraction of ICAM-1 in the blood of hepatocellular carcinoma patients correlated positively with a better OS and a lower recurrence rate but was also predictive of a poor response to immune checkpoint inhibition [178]. Here, ICAM1 is linked to hepatocellular carcinoma.